487 related articles for article (PubMed ID: 28511073)
1. Preparation and evaluation of L- and D-5-[
Tang T; Gill HS; Ogasawara A; Tinianow JN; Vanderbilt AN; Williams SP; Hatzivassiliou G; White S; Sandoval W; DeMent K; Wong M; Marik J
Nucl Med Biol; 2017 Aug; 51():10-17. PubMed ID: 28511073
[TBL] [Abstract][Full Text] [Related]
2. Fully automated radiosynthesis of N(1)-[(18)F]fluoroethyl-tryptophan and study of its biological activity as a new potential substrate for indoleamine 2,3-dioxygenase PET imaging.
Henrottin J; Lemaire C; Egrise D; Zervosen A; Van den Eynde B; Plenevaux A; Franci X; Goldman S; Luxen A
Nucl Med Biol; 2016 Jun; 43(6):379-89. PubMed ID: 27260779
[TBL] [Abstract][Full Text] [Related]
3. Improved Radiosynthesis and Biological Evaluations of L- and D-1-[
Xin Y; Cai H
Mol Imaging Biol; 2017 Aug; 19(4):589-598. PubMed ID: 27815661
[TBL] [Abstract][Full Text] [Related]
4. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Cheong JE; Sun L
Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
[TBL] [Abstract][Full Text] [Related]
5. Characterization of indoleamine-2,3-dioxygenase 1, tryptophan-2,3-dioxygenase, and Ido1/Tdo2 knockout mice.
Aslamkhan AG; Xu Q; Loughlin A; Vu H; Pacchione S; Bhatt B; Garfinkel I; Styring TG; LaFranco-Scheuch L; Pearson K; Reynolds S; Li N; Zhou H; Miller JR; Solban N; Bass A; Glaab WE
Toxicol Appl Pharmacol; 2020 Nov; 406():115216. PubMed ID: 32871117
[TBL] [Abstract][Full Text] [Related]
6. Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening.
Sari S; Tomek P; Leung E; Reynisson J
Molecules; 2019 Nov; 24(23):. PubMed ID: 31795096
[TBL] [Abstract][Full Text] [Related]
7. Fluorine-18-Labeled PET Radiotracers for Imaging Tryptophan Uptake and Metabolism: a Systematic Review.
John F; Muzik O; Mittal S; Juhász C
Mol Imaging Biol; 2020 Aug; 22(4):805-819. PubMed ID: 31512038
[TBL] [Abstract][Full Text] [Related]
8. A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
Klar R; Michel S; Schell M; Hinterwimmer L; Zippelius A; Jaschinski F
Cancer Immunol Immunother; 2020 Jan; 69(1):57-67. PubMed ID: 31802183
[TBL] [Abstract][Full Text] [Related]
9. Deletion of TDO2, IDO-1 and IDO-2 differentially affects mouse behavior and cognitive function.
Too LK; Li KM; Suarna C; Maghzal GJ; Stocker R; McGregor IS; Hunt NH
Behav Brain Res; 2016 Oct; 312():102-17. PubMed ID: 27316339
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Novel Inhibitors of Tryptophan Dioxygenases for Enzyme and Species Selectivity Using Engineered Tumour Cell Lines Expressing Either Murine or Human IDO1 or TDO2.
Tijono SM; Palmer BD; Tomek P; Flanagan JU; Henare K; Gamage S; Braun L; Ching LM
Pharmaceuticals (Basel); 2022 Aug; 15(9):. PubMed ID: 36145311
[TBL] [Abstract][Full Text] [Related]
11. Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors.
Naing A; Eder JP; Piha-Paul SA; Gimmi C; Hussey E; Zhang S; Hildebrand V; Hosagrahara V; Habermehl C; Moisan J; Papadopoulos KP
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32843490
[TBL] [Abstract][Full Text] [Related]
12. Radiosynthesis and biological evaluation of 5-(3-[18F]fluoropropyloxy)-L-tryptophan for tumor PET imaging.
He S; Tang G; Hu K; Wang H; Wang S; Huang T; Liang X; Tang X
Nucl Med Biol; 2013 Aug; 40(6):801-7. PubMed ID: 23791401
[TBL] [Abstract][Full Text] [Related]
13. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism.
Löb S; Königsrainer A; Zieker D; Brücher BL; Rammensee HG; Opelz G; Terness P
Cancer Immunol Immunother; 2009 Jan; 58(1):153-7. PubMed ID: 18418598
[TBL] [Abstract][Full Text] [Related]
14. Tryptophan catabolism is dysregulated in leiomyomas.
Chuang TD; Quintanilla D; Boos D; Khorram O
Fertil Steril; 2021 Oct; 116(4):1160-1171. PubMed ID: 34116832
[TBL] [Abstract][Full Text] [Related]
15. Indoleamine 2,3-dioxygenase 1 deficiency attenuates CCl4-induced fibrosis through Th17 cells down-regulation and tryptophan 2,3-dioxygenase compensation.
Zhong W; Gao L; Zhou Z; Lin H; Chen C; Huang P; Huang W; Zhou C; Huang S; Nie L; Liu Y; Chen Y; Zhou D; Lv Z
Oncotarget; 2017 Jun; 8(25):40486-40500. PubMed ID: 28465467
[TBL] [Abstract][Full Text] [Related]
16. Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease.
Mazarei G; Budac DP; Lu G; Adomat H; Tomlinson Guns ES; Möller T; Leavitt BR
J Neurochem; 2013 Dec; 127(6):852-67. PubMed ID: 23786539
[TBL] [Abstract][Full Text] [Related]
17. Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases IDOs from monotremes and marsupials.
Yuasa HJ; Ball HJ; Ho YF; Austin CJ; Whittington CM; Belov K; Maghzal GJ; Jermiin LS; Hunt NH
Comp Biochem Physiol B Biochem Mol Biol; 2009 Jun; 153(2):137-44. PubMed ID: 19402226
[TBL] [Abstract][Full Text] [Related]
18. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Kim M; Tomek P
Front Immunol; 2021; 12():636081. PubMed ID: 33708223
[TBL] [Abstract][Full Text] [Related]
19. Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod.
Lukas RV; Juhász C; Wainwright DA; James CD; Kennedy E; Stupp R; Lesniak MS
J Neurooncol; 2019 Jan; 141(1):111-120. PubMed ID: 30415456
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of 6-[18F]fluoro-3-(pyridin-3-yl)-1H-indole as potential PET tracer for targeting tryptophane 2, 3-dioxygenase (TDO).
Qiao Z; Mardon K; Stimson DHR; Migotto MA; Reutens DC; Bhalla R
Nucl Med Biol; 2020; 84-85():1-10. PubMed ID: 31927462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]